Brepocitinib significantly improved overall symptom status in a phase III trial
— Brepocitinib significantly improved overall symptom status in a phase III trial
August 27, 2026
• 2 min read
The FDA approved the first oral treatment option for the autoimmune disorder dermatomyositis.
Brepocitinib (Lisraya) is indicated for adults with the rare condition, which causes chronic inflammation, progressive muscle weakness, and skin rashes. The oral drug addresses a longstanding need for patients who have few treatment options for symptom control.
FDA approves Lisraya as first oral drug for dermatomyositis
Brepocitinib yields ‘consistent’ improvements in cutaneous dermatomyositis
FDA green lights Priovant drug for rare skin disease
Roivant’s road to a potential blockbuster begins with Lisraya FDA approval
FDA approves Roivant therapy for rare autoimmune disease
Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
The FDA has approved Lisraya for the treatment of dermatomyositis in adults, the agency announced in a press release. The…
DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according…
Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with…
Brepocitinib improved skin-specific symptoms of dermatomyositis, according to an analysis of the phase 3 VALOR trial published in…
Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned…
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across…
